biospectrumasiaSeptember 03, 2018
Tag: Chugai , Gazyva , Nippon Shinyaku , Japan
Tokyo based Chugai Pharmaceutical and Nippon Shinyaku have launched Gazyva (obinutuzumab), an anti-CD20 monoclonal antibody, as a treatment for follicular lymphoma in Japan.
The companies intend to work closely to make Gazyva contribute to the treatment of patients with CD20-positive follicular lymphoma as one of the standard therapies.
Chugai, which is majority-owned by Swiss pharma giant Roche, obtained a manufacturing and marketing approval in early July.
The product is supported by strong efficacy data from the Phase lll GALLIUM study.
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: